Autologous anti-CD19 CAR T-cell therapy with axicabtagene ciloleucel (axi-cel) induced ORR and complete response (CR) rates of 83 and 58%, respectively, among patients with R/R large B-cell lymphoma in the multicenter ZUMA-1 trial; responses were sustained among 39% of patients with a median follow up time of ~27 months (10, 11). This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.